reports
Nationgate Holdings Berhad: 2 directors
Two Directors at Nationgate Holdings Berhad sold 680,000 shares at between 1.844MYR and 1.853MYR. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
Dätwyler Holding AG: 1 director
A director at Dätwyler Holding AG sold 1,000 shares at 201.000CHF and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Rakta Paper Manufacturing: 1 director
A director at Rakta Paper Manufacturing bought 103,804 shares at 0.000EGP and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Malaysian Pacific Industries Berhad: 1 director
A director at Malaysian Pacific Industries Berhad sold 138,000 shares at 38.171MYR and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
HCK Capital Group Berhad: 1 director
A director at HCK Capital Group Berhad bought 1,950,000 shares at 2.140MYR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Gamuda Berhad: 4 directors
Four Directors at Gamuda Berhad sold 125,000 shares at between 5.621MYR and 5.930MYR. The significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
BNP Paribas Bank Polska S.A.: 1 director
A director at BNP Paribas Bank Polska S.A. sold 4,495 shares at 94.000PLN and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Kinergy Advancement Berhad: 1 director
A director at Kinergy Advancement Berhad sold 15,600,000 shares at 0.320MYR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
GoldenPeaks Capital and Reckitt have signed a 10-year Power Purchase A...
GoldenPeaks Capital Holding Ltd. / Key word(s): Agreement GoldenPeaks Capital and Reckitt have signed a 10-year Power Purchase Agreement in Poland. 21.05.2024 / 14:00 CET/CEST Warsaw, May 21, 2024 - GoldenPeaks Capital and Reckitt have signed a 10-year Power Purchase Agreement in Poland, promoting further decarbonization of the country’s grid and helping Reckitt meet its green goals. GoldenPeaks Capital, one of the fastest growing independent power producers in Eastern Europe, continues its mission to help corporates in their carbon reduction efforts. The power purchase agr...
GoldenPeaks Capital und Reckitt haben in Polen einen Stromabnahmevertr...
GoldenPeaks Capital Holding Ltd. / Schlagwort(e): Vereinbarung GoldenPeaks Capital und Reckitt haben in Polen einen Stromabnahmevertrag mit einer Laufzeit von 10 Jahren unterzeichnet. 21.05.2024 / 14:00 CET/CEST Warschau, 21. Mai 2024 – GoldenPeaks Capital und Reckitt haben in Polen einen Stromabnahmevertrag mit einer Laufzeit von 10 Jahren unterzeichnet, der die weitere Dekarbonisierung des Stromnetzes des Landes vorantreibt und Reckitt dabei hilft, seine grünen Ziele zu erreichen. GoldenPeaks Capital, einer der am schnellsten wachsenden unabhängigen Stromerzeuger in Osteu...
- Gary Brode
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrat...
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces data from a poster presented at Digestive Disease Week (DDW2024) demonstrating the potential of the Company’s lead clinical-stage compound, FXR314, in combination with tofaciti...
Pyxis Tankers Announces Joint Venture Agreement to Acquire Modern Dry-...
Pyxis Tankers Announces Joint Venture Agreement to Acquire Modern Dry-Bulk Vessel, Expansion of Common Share Repurchase Program & Partial Redemption of Series A Cumulative Convertible Preferred Stock Maroussi, Greece – May 21, 2024 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), (“we”, “our”, “us”, the “Company” or “Pyxis Tankers”), an international shipping company, announced today key strategic and financial actions to further enhance its shareholder value. The Company has entered into an agreement with a group of sellers, including the Company’s Chairman and Chief Executive Officer, Mr...
Karat Packaging to Participate in Two June Investor Conferences
Karat Packaging to Participate in Two June Investor Conferences CHINO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Karat Packaging Inc. (Nasdaq: KRT) (“Karat”), a specialty distributor and manufacturer of disposable foodservice products and related items, today announced that it will participate in two investor conferences in June. On June 4, 2024 at 11:30 a.m. ET, Karat’s Chief Executive Officer Alan Yu and Chief Financial Officer Jian Guo will participate in a fireside chat at the Stifel 2024 Cross Sector Insight Conference, taking place at the InterContinental Boston Hotel. On June 5, 2...
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Co...
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of IBSRELA® (tenapanor) was presented at the 2024 Digestive Disease Week Conference (DDW), currently taking place in...
EQS-News: Batteriekühlsysteme für neue E-Busse: technotrans sichert si...
EQS-News: technotrans SE / Schlagwort(e): Sonstiges Batteriekühlsysteme für neue E-Busse: technotrans sichert sich Großauftrag 21.05.2024 / 13:57 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Batteriekühlsysteme für neue E-Busse: technotrans sichert sich Großauftrag Großvolumenauftrag im hohen einstelligen Millionen-Euro-Bereich Serienfertigung von Batterie-Thermomanagement-Systemen (BTMS) für mehrere E-Bus-Serien Wachstumsbeschleuniger im technotrans-Fokusmarkt Energy Management und Meilenstein im Segment Straßenfahrzeuge Sassen...
EQS-News: Battery cooling systems for new e-buses: technotrans secures...
EQS-News: technotrans SE / Key word(s): Miscellaneous Battery cooling systems for new e-buses: technotrans secures major order 21.05.2024 / 13:57 CET/CEST The issuer is solely responsible for the content of this announcement. Battery cooling systems for new e-buses: technotrans secures major order Large-volume order in the high single-digit million euro range Series production of battery thermal management systems (BTMS) for several e-bus series Growth accelerator in technotrans' focus market Energy Management and milestone in the road vehicles segment Sassenberg, 21 M...
Alvotech and Dr. Reddy’s enter into collaboration for commercializatio...
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)Alvotech will be responsible for development and manufacture of the product HYDERABAD, INDIA & REYKJAVIK, ICELAND — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Red...
Alvotech gengur til samstarfs við Dr. Reddy‘s um markaðssetningu AVT03...
Alvotech gengur til samstarfs við Dr. Reddy‘s um markaðssetningu AVT03, fyrirhugaðrar hliðstæðu við Prolia og Xgeva, í Bandaríkjunum og Evrópu Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gert samstarfssamning við Dr. Reddy’s Laboratories SA, dótturfyrirtæki Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) um sölu- og markaðssetningu AVT03, fyrirhugaðrar líftæknilyfjahliðstæðu Alvotech við Prolia og Xgeva, sem bæði innnihalda denosumab. Dr. Reddy er alþjóðlegt lyfjafyrirtæki með höfuðstöðvar á Indlandi en starfsemi um allan heim. Prolia og Xgeva eru líftæknilyf við ýmsum þr...
KANZHUN LIMITED Announces Board Changes
KANZHUN LIMITED Announces Board Changes BEIJING, May 21, 2024 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HKEX: 2076), a leading online recruitment platform in China, today announced that Ms. Shangyu Gao has resigned as an independent non-executive director of the Company in order to devote more time to her other personal business commitments, effective on May 21, 2024. In addition, with effect from May 21, 2024, Ms. Mengyuan Dong has been appointed as an independent non-executive director of the Company, the chairman of the audit committee, a member...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.